Современная онкология (Dec 2023)
Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”
- Valeriy V. Breder,
- Liudmila G. Zhukova,
- Larisa V. Bolotina,
- Irina A. Demidova,
- Yaroslav A. Zhulikov,
- Elena V. Lubennikova,
- David R. Naskhletashvili,
- Sergey V. Orlov,
- Rashida V. Orlova,
- Ilya S. Romanov,
- Nikita A. Savelov,
- Ksenia A. Sarantseva,
- Alexandra S. Tyulyandina,
- Mikhail Yu. Fedyanin
Affiliations
- Valeriy V. Breder
- ORCiD
- Blokhin National Medical Research Center of Oncology
- Liudmila G. Zhukova
- ORCiD
- Loginov Moscow Clinical Scientific Center
- Larisa V. Bolotina
- ORCiD
- Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
- Irina A. Demidova
- Moscow City Oncology Hospital №62
- Yaroslav A. Zhulikov
- ORCiD
- Blokhin National Medical Research Center of Oncology
- Elena V. Lubennikova
- ORCiD
- Blokhin National Medical Research Center of Oncology
- David R. Naskhletashvili
- ORCiD
- Blokhin National Medical Research Center of Oncology
- Sergey V. Orlov
- ORCiD
- Pavlov First Saint Petersburg State Medical University
- Rashida V. Orlova
- ORCiD
- Saint Petersburg State University
- Ilya S. Romanov
- ORCiD
- Blokhin National Medical Research Center of Oncology
- Nikita A. Savelov
- ORCiD
- Moscow City Oncology Hospital №62
- Ksenia A. Sarantseva
- ORCiD
- Blokhin National Medical Research Center of Oncology
- Alexandra S. Tyulyandina
- ORCiD
- Blokhin National Medical Research Center of Oncology
- Mikhail Yu. Fedyanin
- ORCiD
- Blokhin National Medical Research Center of Oncology
- DOI
- https://doi.org/10.26442/18151434.2023.3.202441
- Journal volume & issue
-
Vol. 25,
no. 3
pp. 295 – 300
Abstract
NTRK-fusion positive tumors are a rare finding, but targeted therapy demonstrates persistent and sustained systemic and intracranial responses to entrectinib. This resolution proposes algorithms for diagnosing NTRK translocations in various solid tumors and discuses clinical data on the efficacy and safety of entrectinib.
Keywords
